


L1 HAS NO ANSWERS  
L1 STR



G1 N, C

G2 H, Me, Et, n-Pr, i-Pr, n-Bu, i-Bu, s-Bu, t-Bu

Structure attributes must be viewed using STN Express query preparation.

=> s ll,ful

FULL SEARCH INITIATED 10:33:41 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 219713 TO ITERATE

100.0% PROCESSED 219713 ITERATIONS  
SEARCH TIME: 00.00.03

187 ANSWERS

L2 187 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 10:33:55 ON 24 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Jan 2007 VOL 146 ISS 5  
FILE LAST UPDATED: 23 Jan 2007 (20070123/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12

L3 5 L2

=> d ibi abs hitstr 1-5

'IBI' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB  
ALL ----- BIB, AB, IND, RE  
APPS ----- AI, PRAI  
BIB ----- AN, plus Bibliographic Data and PI table (default)  
CAN ----- List of CA abstract numbers without answer numbers  
CBIB ----- AN, plus Compressed Bibliographic Data  
CLASS ----- IPC, NCL, ECLA, FTERM  
DALL ----- ALL, delimited (end of each field identified)  
DMAX ----- MAX, delimited for post-processing  
FAM ----- AN, PI and PRAI in table, plus Patent Family data  
FBIB ----- AN, BIB, plus Patent FAM  
IND ----- Indexing data  
IPC ----- International Patent Classifications  
MAX ----- ALL, plus Patent FAM, RE  
PATS ----- PI, SO  
SAM ----- CC, SX, TI, ST, IT  
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;  
SCAN must be entered on the same line as the DISPLAY,  
e.g., D SCAN or DISPLAY SCAN)  
STD ----- BIB, CLASS  
  
IABS ----- ABS, indented with text labels  
IALL ----- ALL, indented with text labels  
IBIB ----- BIB, indented with text labels  
IMAX ----- MAX, indented with text labels  
ISTD ----- STD, indented with text labels  
  
OBIB ----- AN, plus Bibliographic Data (original)  
OIBIB ----- OIBIB, indented with text labels  
  
SBIB ----- BIB, no citations  
SIBIB ----- IBIB, no citations  
  
HIT ----- Fields containing hit terms  
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
containing hit terms  
HITRN ----- HIT RN and its text modification  
HITSTR ----- HIT RN, its text modification, its CA index name, and  
its structure diagram  
HITSEQ ----- HIT RN, its text modification, its CA index name, its  
structure diagram, plus NTE and SEQ fields

FHITSTR ----- First HIT RN, its text modification, its CA index name, and  
its structure diagram  
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its  
structure diagram, plus NTE and SEQ fields  
KWIC ----- Hit term plus 20 words on either side  
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.  
ENTER DISPLAY FORMAT (BIB):end

=> d his

(FILE 'HOME' ENTERED AT 10:33:01 ON 24 JAN 2007)

FILE 'REGISTRY' ENTERED AT 10:33:18 ON 24 JAN 2007

L1 STRUCTURE UPLOADED  
L2 187 S L1 FUL

FILE 'CAPLUS' ENTERED AT 10:33:55 ON 24 JAN 2007


L3 5 S L2

=> d ibib abs hitstr L3 1-5

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2005:962241 CAPLUS  
 DOCUMENT NUMBER: 143:266825  
 TITLE: Preparation of dihydropyridinone derivatives for heart and lung disease treatment  
 INVENTOR(S): Gielen-Heertwig, Heike; Albrecht, Barbara; Bauser, Marcus; Keldenich, Joerg; Li, Volkhard  
 Pernerstorfer, Josef; Schlemmer, Karl-Heinz; Telan, Leila  
 PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany  
 SOURCE: ECF Int. Appl., 85 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE  
 WO 2005080372 A1 20050901 WO 2005-EPI192 20050205  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZH, ZM, ZW, AG, BG, BR, BY, CA, CH, CN, CU, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2556463 A1 20050901 CA 2005-2556463 20050205  
 EP 1720857 A1 20061115 EP 2005-701362 20050205  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR  
 PRIORITY APPL. INFO.: A 20040219  
 WO 2005-EPI192 W 20050205  
 OTHER SOURCE(S): MARPAT 143:266825  
 GI


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB The invention relates to novel dihydropyridinone derivs., processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development. I was prepared from the corresponding pyridinone-3-carboxylic acid, the synthesis of which is given, and 1-phenylpiperazine. Examples are also given for human neutrophil elastase assays, PMN elastolysis assays, acute lung injury model in rats, and acute myocardial infarction model in rats.

IT 863645-30-1P 863645-32-3P 863645-33-4P  
 863645-34-5P 863645-35-6P 863645-36-7P  
 863645-37-8P 863645-38-9P 863645-40-3P  
 863645-41-4P 863645-42-5P 863645-43-6P  
 863645-44-7P 863645-45-8P 863645-46-9P  
 863645-47-0P 863645-48-1P 863645-49-2P  
 863645-50-5P 863645-51-6P 863645-52-7P  
 863645-53-8P 863645-54-9P 863645-55-0P  
 863645-56-1P 863645-57-2P 863645-58-3P  
 863645-59-4P 863645-60-7P 863645-61-8P  
 863645-62-9P 863645-63-0P 863645-64-1P  
 863645-65-2P 863645-66-3P 863645-67-4P  
 863645-68-5P 863645-69-6P 863645-70-9P  
 863645-71-0P 863645-72-1P 863645-73-2P  
 863645-74-3P 863645-75-4P 863645-76-5P  
 863645-77-6P 863645-78-7P 863645-79-8P  
 863645-80-1P 863645-81-2P 863645-82-3P  
 863645-83-4P 863645-84-5P 863645-85-6P  
 863645-86-7P 863645-87-8P 863645-88-9P  
 863645-89-0P 863645-90-3P 863645-91-4P  
 863645-92-5P 863645-93-6P 863645-94-7P  
 863645-95-8P 863645-96-9P 863645-97-0P  
 863645-98-1P 863645-99-2P 863646-00-8P  
 863646-01-9P 863646-02-0P 863646-03-1P  
 863646-04-2P 863646-05-3P 863646-06-4P  
 863646-07-5P


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of dihydropyridinone derivs. for heart and lung disease treatment)  
 RN 863645-30-1 CAPLUS  
 CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 863645-32-3 CAPLUS  
 CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-cyclohexyl- (9CI) (CA INDEX NAME)




RN 863645-33-4 CAPLUS  
 CN 4-Piperidinol, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 863645-34-5 CAPLUS  
 CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-cycloheptyl- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863645-35-6 CAPLUS  
 CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 863645-36-7 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-cyclohexyl-1,2,3,4-tetrahydro-N,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-37-8 CAPLUS  
 CN Thiomorpholine, 4-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 863645-38-9 CAPLUS  
CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 863645-40-3 CAPLUS  
CN 1-Piperazineethanamine, 4-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863645-44-7 CAPLUS  
CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-(4-acetylphenyl)- (9CI) (CA INDEX NAME)




RN 863645-45-8 CAPLUS  
CN Piperidine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 863645-46-9 CAPLUS  
CN Quinoline, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-1,2,3,4-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863645-41-4 CAPLUS  
CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 863645-42-5 CAPLUS  
CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-43-6 CAPLUS  
CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863645-47-0 CAPLUS  
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N,6-dimethyl-N-(4-methylphenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-48-1 CAPLUS  
CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-[(2,4,6-trimethylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 863645-49-2 CAPLUS  
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-phenyl-N-(phenylmethyl)-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863645-50-5 CAPLUS  
CN 3-Pyridinecarboxamide,  
5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-((4-methoxyphenyl)methyl)-N,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-  
(9CI) (CA INDEX NAME)




RN 863645-51-6 CAPLUS  
CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)




RN 863645-52-7 CAPLUS  
CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-(phenylmethyl)-  
(9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 863645-55-0 CAPLUS  
CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-(4-pyridinyl)-  
(9CI) (CA INDEX NAME)



RN 863645-56-1 CAPLUS  
CN 1H-1,4-Diazepine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 863645-57-2 CAPLUS  
CN 1H-Azepine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]hexahydro- (9CI)  
(CA INDEX NAME)




RN 863645-58-3 CAPLUS  
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N,6-dimethyl-N-(3-methylphenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI)  
(CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 863645-53-8 CAPLUS  
CN 1-Piperazinepropanamine,  
4-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 863645-54-9 CAPLUS  
CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-cyclopentyl-  
(9CI) (CA INDEX NAME)




L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863645-59-4 CAPLUS  
CN 1,4'-Bipiperidine, 1'-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-3-(1-methyl-2-pyrrolidinyl)- (9CI)  
(CA INDEX NAME)




RN 863645-60-7 CAPLUS  
CN Piperidine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-3-(1-methyl-2-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 863645-61-8 CAPLUS  
CN 2-Piperidinecarboxylic acid, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863645-62-9 CAPLUS  
 CN Piperidine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 863645-63-0 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N,6-dimethyl-N-[2-(methylphenylamino)ethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-64-1 CAPLUS  
 CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863645-68-5 CAPLUS  
 CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 863645-69-6 CAPLUS  
 CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 863645-70-9 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-cyclohexyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-[2-(2-pyridinyl)ethyl]-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863645-65-2 CAPLUS  
 CN Pyrrolo[1,2-a]pyrazine, 2-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]octahydro- (9CI) (CA INDEX NAME)




RN 863645-66-3 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-(cyclopropylmethyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-propyl-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-67-4 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-acetyl-N-(2-cyanoethyl)-4-(4-cyanophenyl)-N-ethyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863645-71-0 CAPLUS  
 CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-[(tetrahydro-2-furyl)methyl]- (9CI) (CA INDEX NAME)




RN 863645-72-1 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-acetyl-N-butyl-N-(cyanomethyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-73-2 CAPLUS  
 CN 1-Piperazineacetic acid, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863645-74-3 CAPLUS  
CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 863645-75-4 CAPLUS  
CN Piperidine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)




RN 863645-76-5 CAPLUS  
CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 863645-80-1 CAPLUS  
CN Azetidine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-3-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 863645-81-2 CAPLUS  
CN Azetidine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-3-phenoxy- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863645-77-6 CAPLUS  
CN N-Alanine, N-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-N-cyclopropyl-ethyl ester (9CI) (CA INDEX NAME)




RN 863645-78-7 CAPLUS  
CN Carbamic acid, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-piperidinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 863645-79-8 CAPLUS  
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-cyclohexyl-N-(3-turanylmethyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863645-82-3 CAPLUS  
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N,6-dimethyl-N-[(3-nitrophenyl)methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-83-4 CAPLUS  
CN Quinoline, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-6-fluoro-1,2,3,4-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 863645-84-5 CAPLUS  
CN 4-Piperidinone, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-,  
4-(O-methyloxime) (9CI) (CA INDEX NAME)



RN 863645-85-6 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 863645-86-7 CAPLUS  
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-[[4-(diethylamino)phenyl]methyl]-1,2,3,4-tetrahydro-N,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-87-8 CAPLUS  
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-[(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 863645-91-4 CAPLUS  
CN 3-Pyridinecarboxamide, 5-acetyl-N-(2-(2-chlorophenyl)ethyl)-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-92-5 CAPLUS  
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-[[2-(2-methoxyethoxy)propyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-93-6 CAPLUS  
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-[(2-phenoxyethyl)-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
(CA INDEX NAME)



RN 863645-88-9 CAPLUS  
CN Piperazine, 1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 863645-89-0 CAPLUS  
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-[[2-(4-hydroxy-3-methoxyphenyl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-90-3 CAPLUS  
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-N-[[2-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 863645-94-7 CAPLUS  
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-[[4,6-dimethyl-2-pyrimidinyl]methyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 863645-95-8 CAPLUS  
CN 3-Pyridinecarboxamide, 5-acetyl-N-[(2-chlorophenyl)methyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-96-9 CAPLUS  
CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-[[4-(trifluoromethoxy)phenyl]methyl]-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863645-97-0 CAPLUS  
CN 3-Pyridinecarboxamide, 5-acetyl-N-[(3-chlorophenyl)methyl]-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863645-98-1 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-N-[(3-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 863645-99-2 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-(2,4-dimethylphenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863646-00-8 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-(4-methyl-1-piperazinyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863646-04-2 CAPLUS  
 CN Benzoic acid, 4-[[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 863646-05-3 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-(3,5-dimethylphenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863646-06-4 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-[2-(3-methoxyphenyl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863646-01-9 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-[2-(3,4-dimethylphenyl)ethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863646-02-0 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-[2-(4-hydroxy-3,5-dimethoxyphenyl)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 863646-03-1 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-[2-(methylphenylamino)ethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 863646-07-5 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-N-[2-(2-methoxyphenyl)-1-piperazinyl]propyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 ACCESSION NUMBER: 2004:203810 CAPLUS  
 DOCUMENT NUMBER: 140:235612  
 TITLE: Preparation of dihydropyridinones as human neutrophil elastase (HNE) inhibitors  
 INVENTOR(S): Gielen, Heike; Li, Volkhard Min-Jian; Rosentreter, Ulrich; Schlemmer, Karl-Heinz; Allerheiligen, Sven; Telan, Leila; Baerfacker, Lars; Keldenich, Joerg; Fitzgerald, Mary F.; Nash, Kevin; Albrecht, Barbara; Meurer, Dirk  
 PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany  
 SOURCE: PCT Int. Appl., 166 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO. KIND DATE APPLICATION NO. DATE  
 WO 2004020410 A2 20040311 WO 2003-EP9108 20030818  
 WO 2004020410 A3 20040422  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW  
 RW: GH, GN, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2496815 A1 20040311 CA 2003-2496815 20030818  
 AU 2003293356 A1 20040319 AU 2003-293356 20030818  
 EP 1554246 A2 20050720 EP 2003-790904 20030818  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, JP 2006503820 T 20060202 JP 2004-532090 20030818  
 US 2006100207 A1 20060511 US 2005-525608 20051013  
 GB 2002-19894 A 20020827  
 GB 2002-21143 A 20020912  
 WO 2003-EP9108 W 20030818

OTHER SOURCE(S): MARPAT 140:235612  
 GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [wherein A = hetero/aryl; R1, R2, R3 = independently H, halo, NO2, CN, CF3, OCF3, (un)substituted alkyl, OH and deriva.. R4 = alkenoxycarbonyl, hydroxycarbonyl, CN, (un)substituted alkylcarbonyl,

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 (Process): USES (Uses)  
 (human neutrophil elastase inhibitor; prepn. of dihydropyridinones as human neutrophil elastase inhibitors)  
 RN 668998-87-6 CAPLUS  
 CN 3,5-Pyridinedicarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 668998-93-4 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 668999-86-8P 669000-45-7P, (+)-Diethyl 4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3,5-pyridinedicarboxylate  
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (human neutrophil elastase inhibitor; preparation of dihydropyridinones as human neutrophil elastase inhibitors)  
 RN 668999-86-8 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, (3R,4S)-rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 alkoxy, alkoxy, alkyl, cycloalkyl, N-(heterocyclyl)/mono/di/aminocarbonyl; R5 = alkyl; R6 = H, CN, cycloalkyl/alkyl/aminocarbonyl, cycloalkylcarbonyl, arylcarbonyl, hydroxycarbonyl, alkenoxycarbonyl, aryloxy, (un)substituted mono/di/aryl/aminocarbonyl, alkylcarbonyl, alkoxy, alkoxy, or R6 = 4-carboxypiperazinyl and deriva., 4-carboxymorpholinyl, etc.; R7 = H, halo, NO2, CN, CF3, OCF3, (un)substituted alkyl, alkoxy; Y1, Y2, Y3, Y4, Y5 = independently CH or N; and their salts, hydrates, and/or solvates, and their tautomeric forms)  
 were prepd. as human neutrophil elastase (HNE) inhibitors. For example, II was prepd. by cyclocondensation of III (prepn. given) with 4-formylbenzonitrile and 2-cyanoacetamide in the presence of EtOH/piperidine, followed by reaction with water in acetic acid. In an in vitro assay, I inhibited HNE with IC50 values within the range of 5 nM - 5 µM. Thus, I are useful for treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.  
 IT 668998-95-6P  
 RL: BYP (Byproduct); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (human neutrophil elastase inhibitor; preparation of dihydropyridinones as human neutrophil elastase inhibitors)  
 RN 668998-95-6 CAPLUS  
 CN 3,5-Pyridinedicarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 5-[(1R)-1-carboxyethyl]-3-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 668998-87-6P, Diethyl 4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3,5-pyridinedicarboxylate  
 668998-93-4P, 5-Cyano-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinecarboxamide  
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 669000-45-7 CAPLUS  
 CN 3,5-Pyridinedicarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, diethyl ester, (3R,4R)-rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.




IT 668999-32-4P, Allyl 4-(4-cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate  
 668999-33-5P, 4-(4-Cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylic acid  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (human neutrophil elastase inhibitor; preparation of dihydropyridinones as human neutrophil elastase inhibitors)  
 RN 668999-32-4 CAPLUS  
 CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 668999-33-5 CAPLUS  
CN 3-Pyridinecarboxylic acid,  
4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-  
oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 668998-88-7P, Ethyl 5-(aminocarbonyl)-4-(4-cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668998-90-1P, Ethyl 5-acetyl-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinecarboxylate 668998-91-2P, Ethyl 4-(4-cyanophenyl)-5-[(dimethylamino)carbonyl]-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668998-92-3P, Ethyl 5-cyano-4-(4-cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668998-94-5P, Ethyl 5-cyano-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinecarboxylate 668998-97-8P, Ethyl 5-cyano-4-[(4-methoxycarbonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinecarboxylate 668998-98-9P, 5-Cyano-4-(4-cyanophenyl)-N,N-dimethyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinecarboxamide 668998-99-0P, 5-Acetyl-4-(4-cyanophenyl)-N,N-dimethyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinecarboxamide 668999-00-6P, Ethyl 4-(4-cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668999-02-8P, Ethyl 4-(4-cyanophenyl)-5-[(cyclopropylamino)carbonyl]-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668999-03-9P, Ethyl

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
tetrahydropyridine-3-carboxylic acid N-(2-hydroxyethyl)amide 668999-57-3P, 4-(4-Cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyridine-3-carboxylic acid cyclopropylamide 668999-58-4P 668999-59-5P 668999-60-8P 668999-61-9P 668999-62-0P 668999-63-1P 668999-64-2P 668999-65-3P 668999-66-4P 668999-67-5P 668999-68-6P 668999-69-7P 668999-70-0P 668999-71-1P 668999-72-2P 668999-73-3P 668999-74-4P 668999-75-5P 668999-76-6P 668999-77-7P, 4-(4-Cyanophenyl)-5-cyclopropylcarbonyl-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydropyridine-3-carboxylic acid ethyl ester 668999-78-8P 668999-79-9P 668999-80-2P 668999-81-3P 668999-82-4P 668999-83-5P 668999-84-6P 668999-85-7P 668999-87-9P, N-[2-(Benzoyloxy)ethyl]-5-cyano-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinecarboxamide 668999-88-0P, 2-[[[5-Cyano-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinyl]carbonyl]amino]ethyl methanesulfonate  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(human neutrophil elastase inhibitor; prepn. of dihydropyridinones as human neutrophil elastase inhibitors)  
RN 668998-88-7 CAPLUS  
CN 3-Pyridinecarboxylic acid, 5-(aminocarbonyl)-4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668998-90-1 CAPLUS  
CN 3-Pyridinecarboxylic acid,  
5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-  
methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
4-(4-cyanophenyl)-5-[(isopropylamino)carbonyl]-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668999-04-0P 668999-05-1P 668999-06-2P, 5-Cyano-4-(4-cyanophenyl)-N-(2-methoxyethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3-pyridinecarboxamide 668999-07-3P 668999-08-4P 668999-09-5P 668999-10-8P 668999-11-9P 668999-12-0P 668999-13-1P 668999-14-2P 668999-15-3P 668999-16-4P 668999-17-5P 668999-18-6P 668999-19-7P, Diethyl 4-(4-cyanophenyl)-6-methyl-2-oxo-5-[(trifluoromethyl)-3,4-dihydro-2H-1,3'-bipyridine-3,5-dicarboxylate 668999-20-0P, Ethyl 4-(4-cyanophenyl)-2-methyl-6-oxo-5-[(1-

pyrrolidinyl)carbonyl]-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668999-21-1P, Ethyl 4-(4-cyanophenyl)-5-[(2-methoxyethyl)(methyl)amino]carbonyl]-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668999-22-2P, Ethyl 4-(4-cyanophenyl)-5-[(diethylamino)carbonyl]-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668999-23-3P, Ethyl 4-(4-cyanophenyl)-2-methyl-5-[(4-morpholinyl)carbonyl]-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668999-24-4P, Ethyl 4-(4-cyanophenyl)-2-methyl-6-oxo-5-[(1,3-thiazolidin-3-yl)carbonyl]-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668999-25-5P, Ethyl 5',6-dicyano-6'-methyl-2'-oxo-1'-[3-(trifluoromethyl)phenyl]-1',2',3',4'-tetrahydro-3',4'-bipyridine-3'-carboxylate 668999-26-6P, 2'-Methyl-6'-oxo-1'-[3-(trifluoromethyl)phenyl]-1',4',5',6'-tetrahydro-3',4'-bipyridine-3',6'-dicarbonitrile 668999-27-7P, Ethyl 4-(4-cyanophenyl)-2-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668999-28-8P, Diethyl 4-(4-chlorophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-3,5-pyridinedicarboxylate 668999-29-9P, 4-(4-Cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668999-30-2P, 4-[5-Acetyl-6-methyl-3-[(4-morpholinyl)carbonyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-4-pyridinyl]benzonitrile 668999-31-3P, 4-[5-Acetyl-6-methyl-3-[(4-morpholinyl)carbonyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-4-pyridinyl]benzonitrile 668999-34-6P, 2-Hydroxyethyl 4-(4-cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668999-35-7P, 2-(Dimethylamino)ethyl 4-(4-cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668999-36-8P 668999-37-9P, 2-(Acetylamino)ethyl 4-(4-cyanophenyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668999-38-0P 668999-39-1P 668999-41-5P 668999-44-8P 668999-45-9P 668999-46-0P 668999-47-1P 668999-48-2P 668999-49-3P 668999-50-6P 668999-51-7P 668999-52-8P 668999-53-9P 668999-54-0P 668999-55-1P, [[[(5-Cyano-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyridin-3-yl)carbonyl]amino]acetic acid 668999-56-2P, 5-Cyano-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668998-91-2 CAPLUS  
CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-5-[(dimethylamino)carbonyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668998-92-3 CAPLUS  
CN 3-Pyridinecarboxylic acid,  
5-cyano-4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-  
methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668998-94-5 CAPLUS  
CN 3,5-Pyridinedicarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 3-ethyl 5-[(1R)-2-methoxy-1-methyl-2-oxoethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668998-96-7 CAPLUS  
 CN 3-Pyridinecarboxylic acid,  
 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-  
 methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668998-97-8 CAPLUS  
 CN 3-Pyridinecarboxylic acid, 5-cyano-1,2,3,4-tetrahydro-4-[(methoxycarbonyl)phenyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668998-98-9 CAPLUS  
 CN 3-Pyridinecarboxamide,  
 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N,N,6-  
 trimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-03-9 CAPLUS  
 CN 3-Pyridinecarboxylic acid,  
 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-5-  
 [(1-methylethylamino)carbonyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668999-04-0 CAPLUS  
 CN β-Alanine, N-[(5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 668999-05-1 CAPLUS  
 CN β-Alanine, N-[(5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668998-99-0 CAPLUS  
 CN 3-Pyridinecarboxamide,  
 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N,N,6-  
 trimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-00-6 CAPLUS  
 CN 3-Pyridinecarboxylic acid,  
 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-  
 oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668999-02-8 CAPLUS  
 CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-5-  
 [(cyclopropylamino)carbonyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 668999-06-2 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-(2-methoxyethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 668999-07-3 CAPLUS  
 CN D-Alanine, N-[(5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 668999-08-4 CAPLUS  
 CN D-Alanine, N-[(5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 668999-09-5 CAPLUS  
 CN D-Alanine, N-[(1S,4S)-5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 668999-10-8 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668999-11-9 CAPLUS


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-14-2 CAPLUS  
 CN 3-Pyridinecarboxamide, 4-(4-bromophenyl)-5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-15-3 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 668999-16-4 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyano-2-methylphenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-N-[(1R)-1-phenylethyl]-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668999-12-0 CAPLUS  
 CN D-Alanine, N-[(1S,4S)-5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 668999-13-1 CAPLUS  
 CN D-Alanine, N-[(1S,4R)-5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-17-5 CAPLUS  
 CN 3-Pyridinecarboxamide, N-(4-bromophenyl)-5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-18-6 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-N-ethyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-19-7 CAPLUS  
 CN 1(2H),2'-Bipyridine]-3,5-dicarboxylic acid, 4-(4-cyanophenyl)-3,4-dihydro-6-methyl-2-oxo-5'-(trifluoromethyl)-, diethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-20-0 CAPLUS  
 CN 3-Pyridinecarboxylic acid,  
 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-5-(1-pyrrolidinylcarbonyl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


$Y = N$   
 546/257  
 514/334



RN 668999-21-1 CAPLUS  
 CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-5-[[2-methoxyethyl]methylamino]carbonyl-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


546/279.1

514/343




RN 668999-22-2 CAPLUS


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-25-5 CAPLUS  
 CN [3,4'-Bipyridine]-3',6-dicarboxylic acid,  
 5',6'-dicyano-1',2',3',4'-tetrahydro-6'-methyl-2'-oxo-1'-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668999-26-6 CAPLUS  
 CN [3,4'-Bipyridine]-3',6-dicarbonitrile,  
 1',4',5',6'-tetrahydro-2'-methyl-6'-oxo-1'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-27-7 CAPLUS  
 CN 3-Pyridinecarboxylic acid,  
 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-5-[[4-methyl-1-piperazinyl]carbonyl]-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-5-[[diethylamino]carbonyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 668999-23-3 CAPLUS  
 CN 3-Pyridinecarboxylic acid,  
 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-5-[[4-morpholinylcarbonyl]-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 668999-24-4 CAPLUS  
 CN 3-Pyridinecarboxylic acid,  
 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-5-[[3-thiazolidinylcarbonyl]-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


544/131

514/235.5


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-28-8 CAPLUS  
 CN 3,5-Pyridinedicarboxylic acid, 4-(4-chlorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 668999-29-9 CAPLUS  
 CN 3-Pyridinecarbonitrile, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 668999-30-2 CAPLUS  
 CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)

546/269.7

514/342

$A = \text{Het}$


514/334

544/365


514/253.12

514/351


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-31-3 CAPLUS  
CN Morpholine, 4-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 668999-34-6 CAPLUS  
CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-hydroxyethyl ester (9CI) (CA INDEX NAME)




RN 668999-35-7 CAPLUS  
CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(dimethylamino)ethyl ester (9CI)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-38-0 CAPLUS  
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-N-[2-[[1,1-dimethylethyl]dimethylsilyloxy]ethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-39-1 CAPLUS  
CN 3-Pyridinecarboxamide, 5-cyano-N-ethyl-1,2,3,4-tetrahydro-6-methyl-4-(4-nitrophenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-41-5 CAPLUS  
CN 3-Pyridinecarboxamide, 5-cyano-1,2,3,4-tetrahydro-6-methyl-4-(4-nitrophenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 668999-36-8 CAPLUS  
CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 668999-37-9 CAPLUS  
CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-(acetylamino)ethyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-44-8 CAPLUS  
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-N-ethyl-1,2,3,4-tetrahydro-6-methyl-1-(3-methylphenyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 668999-45-9 CAPLUS  
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-1-(3-methylphenyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 668999-46-0 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(3-chlorophenyl)-5-cyano-4-(4-cyanophenyl)-N-ethyl-1,2,3,4-tetrahydro-6-methyl-2-oxo- (9CI) (CA INDEX NAME)




L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-47-1 CAPLUS  
CN 3-Pyridinecarboxamide, 1-(3-chlorophenyl)-5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 668999-48-2 CAPLUS  
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-(2-(4-morpholinyl)ethyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-49-3 CAPLUS  
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-(3-methoxypropyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 668999-53-9 CAPLUS  
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-N-[2-(dimethylamino)ethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-54-0 CAPLUS  
CN Glycine, N-[(5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 668999-55-1 CAPLUS  
CN Glycine, N-[(5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-50-6 CAPLUS  
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-(1-methylpropyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-51-7 CAPLUS  
CN 3-Pyridinecarboxamide, N-butyl-5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-52-8 CAPLUS  
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-(2-methylpropyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 668999-56-2 CAPLUS  
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-(2-hydroxyethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 668999-57-3 CAPLUS  
CN 3-Pyridinecarboxamide, 4-(4-cyanophenyl)-N-cyclopropyl-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-58-4 CAPLUS  
CN 3-Pyridinecarboxamide, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-N-[1-(phenylmethyl)-4-piperidinyl]-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-59-5 CAPLUS  
CN 3-Pyridinecarboxamide, N-[(2-chlorophenyl)methyl]-4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-60-8 CAPLUS  
 CN 3-Pyridinecarboxamide, 4-(4-cyanophenyl)-N-[2-(2-fluorophenyl)ethyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-61-9 CAPLUS  
 CN 3-Pyridinecarboxamide, 4-(4-cyanophenyl)-N-[(2-fluorophenyl)methyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-62-0 CAPLUS

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 668999-66-4 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-67-5 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668999-68-6 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN 3-Pyridinecarboxamide, 4-(4-cyanophenyl)-N-[2-(dimethylamino)ethyl]-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 668999-63-1 CAPLUS  
 CN 3-Pyridinecarboxamide, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-N-(2-methoxyethyl)-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-64-2 CAPLUS  
 CN 3-Pyridinecarboxamide, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-N-(2-methylpropyl)-6-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-65-3 CAPLUS  
 CN 3-Pyridinecarboxamide, 4-(4-cyanophenyl)-N-ethyl-1,4,5,6-tetrahydro-2-

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 668999-69-7 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-N-[(1S)-2-(cyclopropylamino)-1-methyl-2-oxoethyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 668999-70-0 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-[(1S)-2-[(2-methoxyethyl)amino]-1-methyl-2-oxoethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 668999-71-1 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-[(1S)-1-methyl-2-(methylamino)-2-oxoethyl]-2-oxo-1-[3-


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN  
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

(Continued)


**Absolute stereochemistry.**



RN 668999-72-2 CAPIUS  
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-[3-(4-morpholinyl)-3-oxopropyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-73-3 CAPLUS  
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-N-[3-(dimethylamino)-3-oxopropyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)




RN 668999-74-4 CAPLUS  
CN 3-Pyridinecarboxamide,  
5-cyano-4-(4-cyanophenyl)-N-[3-(cyclopropylamino)-3-oxopropyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN 668999-78-8 CAPLUS  
CN 3,5-Pyridinedicarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 5-ethyl 3-(2-methoxyethyl) ester (9CI) (CA INDEX NAME)




RN 668999-79-9 CAPLUS  
CN 3,5-Pyridinedicarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 5-ethyl 3-phenyl ester (9CI)  
(CA INDEX NAME)




RN 668999-80-2 CAPLUS  
CN 3,5-Pyridinedicarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 5-ethyl 3-(2-propenyl) ester (SCI) (CA INDEX NAME)

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN  
(9CI) (CA INDEX NAME)


(Continued)



RN 668999-75-5 CAPLUS  
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-N-[3-  
[(2-methoxyethyl)amino]-3-oxopropyl]-6-methyl-2-oxo-1-[3-  
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 668999-76-6 CAPLUS  
CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-[3-(methylamino)-3-oxopropyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-  
(SCI) (CA INDEX NAME)




RN 668999-77-7 CAPLUS  
CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-  
1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl  
ester (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN


(Continued)



RN	668999-81-3	CAPLUS
CN	3-Pyridinecarboxylic acid, 5-[(4-acetyl-1-piperazinyl)carbonyl]-4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)	




RN	668999-82-4	CAPLUS
CN	3-Pyridinecarboxylic acid, 5-[[bis(1-methylethyl)amino]carbonyl]-4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)	




RN 668999-83-5 CAPLUS  
CN 3-Pyridinecarboxylic acid,  
4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-5-  
[(methylphenylamino)carbonyl]-6-oxo-1-[3-(trifluoromethyl)phenyl], ethyl  
ester (9CI) (CA INDEX NAME)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 668999-84-6 CAPLUS  
 CN 3-Pyridinecarboxylic acid,  
 5-benzoyl-4-(4-cyanophenyl)-1,4,5,6-tetrahydro-  
 2-methyl-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA  
 INDEX NAME)




RN 668999-85-7 CAPLUS  
 CN 3-Pyridinecarboxylic acid,  
 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-  
 oxo-5-(1-oxobutyl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA  
 INDEX NAME)




RN 668999-87-9 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-  
 methyl-2-oxo-N-[2-(phenylmethoxy)ethyl]-1-[3-(trifluoromethyl)phenyl]-

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (prepn. of dihydropyridinones as human neutrophil elastase inhibitors)  
 RN 669000-46-8 CAPLUS  
 CN [3,4'-Bipyridine]-3'-carboxamide, 5',6-dicyano-N-ethyl-1',2',3',4'-  
 tetrahydro-6'-methyl-2'-oxo-1'-[3-(trifluoromethyl)phenyl]- (9CI) (CA  
 INDEX NAME)




A = het ✓

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 668999-88-0 CAPLUS  
 CN 3-Pyridinecarboxamide, 5-cyano-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-  
 methyl-N-[2-[(methylsulfonyl)oxy]ethyl]-2-oxo-1-[3-(  
 trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 669000-16-2P, Ethyl 4-(4-chlorophenyl)-2-methyl-6-oxo-1-[3-(  
 trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (intermediate; preparation of dihydropyridinones as human neutrophil  
 elastase inhibitors)

RN 669000-16-2 CAPLUS  
 CN 3-Pyridinecarboxylic acid,  
 4-(4-chlorophenyl)-1,4,5,6-tetrahydro-2-methyl-  
 6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 669000-46-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1991:535744 CAPLUS  
 DOCUMENT NUMBER: 115:135744

TITLE: Preparation of 3-alkyl β-lactams via the ketene  
 imine cycloaddition reaction using  
 α-(phenylthio)alkanol halides as starting  
 materials: application to the synthesis of  
 (±)-carbapenem building blocks and related  
 compounds

AUTHOR(S): Palomo, Claudio; Cossio, Fernando P.; Odiozola, Jose  
 M.; Diarbid, Mikel; Ontoria, Jesus M.  
 CORPORATE SOURCE: Fac. Quim., Univ. Pais Vasco, San Sebastian, 20080,  
 Spain  
 SOURCE: Journal of Organic Chemistry (1991), 56(14), 4418-28  
 CODEN: JOCEAH; ISSN: 0022-3263  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 115:135744  
 GI



AB Preparation of appropriately substituted 3-alkyl β-lactams via the  
 ketene  
 (or equivalent)-imine cycloaddn. reaction is described. The  
 dehydrochlorination of 4-RC6H4SCHRICOC1 (R = H, Me, Cl; R1 = Me, Et,  
 CHMe2) with Et3N in the presence of R2N:CHR3 (R2 = Bz, MeO2C,  
 PhC.tplbond.C, PhCH:CMc, PhCH:CH; R3 = 4-MeOC6H4, MeO2CCH2, PhCH2) or  
 4-MeOC6H4N:CHCR4:CHPh (R4 = H, Me, Ph) produced a high-yield of  
 α-phenylthio β-lactams, which upon desulfuration furnished  
 3-alkyl β-lactams I and II in a highly stereoselective fashion. In  
 contrast, reaction between RCHClCOCl and cinnamylideneamines in the  
 presence of Et3N furnished [4 + 2] cycloadducts as main products.


Preparation  
 of highly functionalized α-alkylidene β-lactams through thermal  
 decomposition of the corresponding β-lactam sulfoxides or by cycloaddn.

of  
 α,β-unsatd. acid chlorides to imino esters in the presence of  
 triethylamine is also described.

IT 135616-42-1P 135616-43-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and dehydrohalogenation of)  
 RN 135616-42-1 CAPLUS  
 CN 2(1H)-Pyridinone,  
 3-chloro-3,4-dihydro-1-(4-methoxyphenyl)-3,5-dimethyl-4-  
 phenyl-, cis- (9CI) (CA INDEX NAME)



Relative stereochemistry.

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 135616-43-2 CAPLUS  
 CN 2(1H)-Pyridinone, 3-bromo-3,4-dihydro-1-(4-methoxyphenyl)-3,5-dimethyl-4-phenyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1984:510786 CAPLUS  
 DOCUMENT NUMBER: 101:110786

TITLE: Mesolonic oxazolones in heterocyclic synthesis:  
 reaction of 1-aza-3-bromo-1,3-butadienes with  
 2-phenyl-4-methyl-Δ<sup>2</sup>-oxazolin-5-one  
 AUTHOR(S): Konwar, Dilip; Sandhu, Jagir; Baruah, J. N.  
 CORPORATE SOURCE: Reg. Res. Lab., Jorhat, 785 006, India  
 SOURCE: Indian Journal of Chemistry, Section B: Organic  
 Chemistry Including Medicinal Chemistry (1983),  
 22B(12), 1248-9  
 CODEN: 1JSBDB; ISSN: 0376-4699

DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 101:110786  
 GI



AB Phenylmethyloxazolinone I reacts with PhCH:CH:CH:NC<sub>6</sub>H<sub>4</sub>R (R = 4-MeO, 4-Cl, 4-Me, 3-NO<sub>2</sub>, 4-Br) to give α-pyridones II in good yields, without the formation of any β-lactams.

IT 91506-98-8P 91506-99-9P 91507-00-5P


91507-01-6P 91507-02-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)


RN 91506-98-8 CAPLUS

CN Benzamide, N-[5-bromo-1,2,3,4-tetrahydro-1-(4-methoxyphenyl)-3-methyl-2-oxo-4-phenyl-3-pyridinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 91506-99-9 CAPLUS  
 CN Benzamide,  
 N-[5-bromo-1-(4-chlorophenyl)-1,2,3,4-tetrahydro-3-methyl-2-oxo-4-phenyl-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 91507-00-5 CAPLUS  
 CN Benzamide,  
 N-[5-bromo-1,2,3,4-tetrahydro-3-methyl-1-(4-methylphenyl)-2-oxo-4-phenyl-3-pyridinyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 91507-01-6 CAPLUS  
 CN Benzamide,  
 N-[5-bromo-1,2,3,4-tetrahydro-3-methyl-1-(3-nitrophenyl)-2-oxo-4-phenyl-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 91507-02-7 CAPLUS  
 CN Benzamide,  
 N-[5-bromo-1-(4-bromophenyl)-1,2,3,4-tetrahydro-3-methyl-2-oxo-4-phenyl-3-pyridinyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1983:453558 CAPLUS  
DOCUMENT NUMBER: 99:53558TITLE: Halogenated ketenes. 38. Cycloaddition of  $\alpha,\beta$ -unsaturated imines with ketenes to yield both  $\beta$ - and  $\delta$ -lactamsAUTHOR(S): Brady, William T.; Shieh, C. H.  
CORPORATE SOURCE: Dep. Chem., North Texas State Univ., Denton, TX, 76203, USASOURCE: Journal of Organic Chemistry (1983), 48(15), 2499-502  
CODEN: JOCEAH; ISSN: 0022-3263DOCUMENT TYPE: Journal  
LANGUAGE: English


OTHER SOURCE(S): CASREACT 99:53558

AB The cycloaddn. of various types of  $\alpha,\beta$ -unsatd. imines with Ph2C:CO and Cl2C:CO yields both (2 + 2) and (4 + 2) cycloaddn. products, i.e.,  $\beta$ -lactams and  $\delta$ -lactams, resp. The cycloaddn. products are dependent upon substitution in the imine and the ketene. The  $\delta$ -lactams derived from Cl2C:CO are easily dehydrochlorinated to the corresponding 2-pyridones. All of the results are consistent with a two-step cycloaddn. process involving a dipolar intermediate.

IT 86129-96-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and dehydrochlorination of)

RN 86129-96-6 CAPLUS

CN 2(1H)-Pyridinone, 3,3-dichloro-3,4-dihydro-5-methyl-1,4-diphenyl- (9CI)  
(CA INDEX NAME)

IT 86129-97-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 86129-97-7 CAPLUS

CN 2(1H)-Pyridinone, 3-chloro-3,4-dihydro-5-methyl-1,4-diphenyl- (9CI) (CA INDEX NAME)

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

